Matinas BioPharma Holdings (Matinas BioPharma Holdings) Intrinsic Value: DCF (Dividends Based) : $ (As of May. 22, 2024)

---

Matinas BioPharma Holdings Intrinsic Value: DCF (Dividends Based) Chart

---

Competitive Comparison of Matinas BioPharma Holdings's Intrinsic Value: DCF (Dividends Based)

For the Biotechnology subindustry, Matinas BioPharma Holdings's Price-to-DCF (Dividends Based), along with its competitors' market caps and Price-to-DCF (Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

Matinas BioPharma Holdings's Price-to-DCF (Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Price-to-DCF (Dividends Based) distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Price-to-DCF (Dividends Based) falls into.

---

Matinas BioPharma Holdings Intrinsic Value: DCF (Dividends Based) Calculation

This is the intrinsic value calculated from the Discounted Dividend Model with default parameters. The calculation method is the same as Discounted Cash Flow model except adjusted dividend are used in the calculation instead of free cash flow. This is the default method of calculation with GuruFocus DCF calculator.

Usually a two-stage model is used in calculating the intrinsic value with discounted cash flow model. The first stage is called growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.

GuruFocus DDM calculator is a two-stage model. The default values are defined as:

1. Discount Rate: d = 11%
A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 4.46%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.

2. Dividend Growth Rate in the growth stage: g1 = %
The Growth Rate in the growth stage is initially set as the default 10-Year Dividend Growth Rate. In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year Dividend Growth Rate. If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year Dividend Growth Rate.
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>

3. Years of Growth Stage: y1 = 10

4. Terminal Growth Rate: g2 = 4%

5. Dividends per Share: adjusted dividends per share = $.
GuruFocus uses adjusted dividends per share by default to ensure that the valuation reflects the total value of the company, as the actual dividend is only a portion of the total value.

All of the default settings can be changed in the DCF calculator and the results are calculated automatically.

Matinas BioPharma Holdings's Intrinsic Value: DCF (Dividends Based) for today is calculated as:

set x = (1+g1)/(1+d) = (1+)/(1+0.11) =
and y = (1+g2)/(1+d) = (1+)/(1+0.11) =

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

Matinas BioPharma Holdings  (AMEX:MTNB) Intrinsic Value: DCF (Dividends Based) Explanation

Unlike valuation methods such as Net Current Asset Value, Tangible Book per Share, Graham Number, Median PS Value etc, discounted Dividends model evaluates the companies based on their power of future dividend distribution instead of their assets.

---

Be Aware

What you need to know about Discounted Dividends model:

1. The Discounted Dividends model evaluates a company based on its future dividends distribution power
2. Dividend growth is taken into account; therefore a company with a higher dividend growth rate is worth more if everything else is the same.
3. Since we are projecting future growth, it is assumed that the company will grow at the same rate as it did during the past 10 years. Therefore this model works better for the companies with consistently steady dividends distributed.
4. The Discounted Dividends model works poorly for inconsistent dividends distributor like high growth companies.
5. Your expected return from the investment is a reasonable discount rate assumption.
6. A larger margin of safety should be required for companies with less dividends distributed.

You can screen for stocks that trade below their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) and Intrinsic Value: DCF (Dividends Based) with the GuruFocus All-in-One Screener. Companies with a high Predictability Rank that trade at a discount to their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) can be found in the screen of Undervalued Predictable Companies.

---

Matinas BioPharma Holdings Intrinsic Value: DCF (Dividends Based) Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Intrinsic Value: DCF (Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictability Rank Intrinsic Value: Projected FCF Intrinsic Value: DCF (FCF Based) Intrinsic Value: DCF (Earnings Based) Margin of Safety % (DCF Dividends Based) Margin of Safety % (DCF FCF Based) Margin of Safety % (DCF Earnings Based) 5-Year Dividend Growth Rate Dividends per Share

---

Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description

Executives

Liu Hui	officer: Chief Technology Officer	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Thomas Hoover	officer: Chief Business Officer	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano	director	8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern	director	STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore	director	17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour	director, officer: Chief Executive Officer	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski	officer: Chief Financial Officer	C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad	director	C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii	officer: Chief Medical Officer	C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits	officer: Chief Development Officer	C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione	officer: Chief Financial Officer	C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler	director	VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino	officer: Chief Scientific Officer	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921